{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:43:06Z","timestamp":1793965386761,"version":"4.8.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Human Genetics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ajhg.2026.05.002","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:57:55Z","timestamp":1779807475000},"page":"1168-1174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Guidance on communication and informed consent with patients and their families for experimental individualized treatments"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-654X","authenticated-orcid":false,"given":"Annemieke","family":"Aartsma-Rus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio M.","family":"de Gusmao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Demarest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Marckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"Favresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Schuele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holm","family":"Graessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy W.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajhg.2026.05.002_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12910-019-0390-x","article-title":"Model consent clauses for rare disease research","volume":"20","author":"Nguyen","year":"2019","journal-title":"BMC Med. Ethics"},{"key":"10.1016\/j.ajhg.2026.05.002_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2307\/3564408","article-title":"Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism","volume":"25","author":"Horng","year":"2003","journal-title":"Irb"},{"key":"10.1016\/j.ajhg.2026.05.002_bib3","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/s41436-021-01245-3","article-title":"Ethical challenges for a new generation of early-phase pediatric gene therapy trials","volume":"23","author":"Iyer","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.ajhg.2026.05.002_bib4","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/ejhg.2016.2","article-title":"Improving the informed consent process in international collaborative rare disease research: effective consent for effective research","volume":"24","author":"Gainotti","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2026.05.002_bib5","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1089\/hum.2005.16.1028","article-title":"Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders","volume":"16","author":"Arkin","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ajhg.2026.05.002_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12910-023-00890-4","article-title":"Improving oncology first-in-human and Window of opportunity informed consent forms through participant feedback","volume":"24","author":"Avinger","year":"2023","journal-title":"BMC Med. Ethics"},{"key":"10.1016\/j.ajhg.2026.05.002_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf346","article-title":"The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing","volume":"53","author":"Belgrad","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ajhg.2026.05.002_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/nat.2022.0060","article-title":"Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides","volume":"33","author":"Aartsma-Rus","year":"2023","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ajhg.2026.05.002_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102615","article-title":"Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation","volume":"36","author":"Sch\u00fcle","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ajhg.2026.05.002_bib10","article-title":"From roadmap to a sustainable end-to-end individualized therapy pathway","volume":"6","author":"Jonker","year":"2025","journal-title":"Ther. Adv. Rare Dis."},{"key":"10.1016\/j.ajhg.2026.05.002_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2021.0039","article-title":"Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives","volume":"32","author":"Synofzik","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ajhg.2026.05.002_bib12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJMra1411250","article-title":"Enduring and emerging challenges of informed consent","volume":"372","author":"Grady","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ajhg.2026.05.002_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41573-024-01059-3","article-title":"The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap","volume":"24","author":"Jonker","year":"2025","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["The American Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002929726001898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002929726001898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:23:50Z","timestamp":1783157030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002929726001898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0002929726001898"],"URL":"https:\/\/doi.org\/10.1016\/j.ajhg.2026.05.002","relation":{},"ISSN":["0002-9297"],"issn-type":[{"value":"0002-9297","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidance on communication and informed consent with patients and their families for experimental individualized treatments","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Human Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajhg.2026.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society of Human Genetics.","name":"copyright","label":"Copyright"}]}}